BioMarin Pharmaceutical Inc

BMRN: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
GkRLOCK|gk?sLOCK|w?H!p%

BioMarin Earnings: Voxzogo Fuels Growth as Pipeline Makes Progress; Shares Undervalued

BioMarin delivered second-quarter revenue of $825 million, representing a 16% increase from the prior year period. GAAP net income increased to $241 million in the second quarter, representing 125% growth year over year.

Sponsor Center